These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 889590)

  • 21. Plasma pharmacokinetics of vinblastine and the investigational Vinca alkaloid N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography.
    van Tellingen O; Beijnen JH; Nooijen WJ; Bult A
    Cancer Res; 1993 May; 53(9):2061-5. PubMed ID: 8481908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans.
    Schran HF; Tse FL
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):1-4. PubMed ID: 3988387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography.
    Jehl F; Quoix E; Leveque D; Pauli G; Breillout F; Krikorian A; Monteil H
    Cancer Res; 1991 Apr; 51(8):2073-6. PubMed ID: 1849042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical pharmacokinetics of vinblastine by continuous intravenous infusion.
    Lu K; Yap HY; Loo TL
    Cancer Res; 1983 Mar; 43(3):1405-8. PubMed ID: 6825110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
    Barnett CJ; Cullinan GJ; Gerzon K; Hoying RC; Jones WE; Newlon WM; Poore GA; Robison RL; Sweeney MJ; Todd GC; Dyke RW; Nelson RL
    J Med Chem; 1978 Jan; 21(1):88-96. PubMed ID: 412968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of gamma-radiation antagonizes the cytotoxic effects of vincristine and vinblastine on both mitotic arrest and apoptosis.
    Sui M; Fan W
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1151-8. PubMed ID: 15752896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
    Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine).
    Rahmani R; Bruno R; Iliadis A; Favre R; Just S; Barbet J; Cano JP
    Cancer Res; 1987 Nov; 47(21):5796-9. PubMed ID: 3664483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacokinetics and metabolism of tofizopam (Grandaxin)].
    Klebovich I; Abermann M
    Acta Pharm Hung; 1993 Mar; 63(2):83-90. PubMed ID: 8100113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of tiropramide after single doses in man.
    Arigoni R; Chisté R; Drovanti A; Makovec F; Senin P; Setnikar I
    Arzneimittelforschung; 1986 Apr; 36(4):738-44. PubMed ID: 3718598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse.
    Dorr RT; Alberts DS
    J Natl Cancer Inst; 1985 Jan; 74(1):113-20. PubMed ID: 3855472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Vinca alkaloid acceptors in P388 murine leukemia cells with a photoactive analogue of vinblastine.
    Safa AR; Glover CJ; Felsted RL
    Cancer Res; 1987 Oct; 47(19):5149-54. PubMed ID: 3621200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity.
    Lobert S; Frankfurter A; Correia JJ
    Cell Motil Cytoskeleton; 1998; 39(2):107-21. PubMed ID: 9484953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of isepamicin.
    Barr WH; Colucci R; Radwanski E; Zampaglione N; Cutler D; Lin CC; Elliott M; Affrime MB
    J Chemother; 1995 Jun; 7 Suppl 2():53-61. PubMed ID: 8622111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolism, excretion, pharmacokinetics and tissue residues of phenylbutazone in the horse.
    Lees P; Taylor JB; Maitho TE; Millar JD; Higgins AJ
    Cornell Vet; 1987 Apr; 77(2):192-211. PubMed ID: 3568689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural basis for the regulation of tubulin by vinblastine.
    Gigant B; Wang C; Ravelli RB; Roussi F; Steinmetz MO; Curmi PA; Sobel A; Knossow M
    Nature; 2005 May; 435(7041):519-22. PubMed ID: 15917812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a sensitive liquid chromatography method coupled with a tandem mass spectrometric detection for the clinical analysis of vinflunine and 4-O-deacetyl vinflunine in blood, urine and faeces.
    Zorza G; Van Heugen JC; De Graeve J; Puozzo C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 853(1-2):294-302. PubMed ID: 17416213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increasing peak levels of vinblastine given in repeated divided doses.
    Van Belle SJ; de Smet MC; De Mey JE; De Neve W; Massart DL; Storme G
    Anticancer Res; 1992; 12(3):655-9. PubMed ID: 1622122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determinants of intrinsic sensitivity to Vinca alkaloids in xenografts of pediatric rhabdomyosarcomas.
    Houghton JA; Williams LG; Torrance PM; Houghton PJ
    Cancer Res; 1984 Feb; 44(2):582-90. PubMed ID: 6692363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disposition of N-methyl-[ring-3,5-3H]tyramine in rabbits and mice.
    Hai H; Guo ZG; Wang JM
    Zhongguo Yao Li Xue Bao; 1989 Jan; 10(1):41-5. PubMed ID: 2816400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.